Skip to main content
Caplight Logo









Shenzhen Readline Biotechnology Co., Ltd.

Shenzhen Readline Biotechnology Co., Ltd.

Private
ShenzhenHealthcare & Life Scienceshttps://www.szreadline.com/

Last Round

Series C

Feb 21, 2025

Total Funding Raised

$157.56M

Company Overview

Shenzhen Readline Biotechnology Co., Ltd. is a biotechnology company that develops immobilized enzyme catalytic technology and provides active ingredients for the pharmaceutical, cosmetic, and nutritional supplement industries.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

IVDin-vitro diagnosticpoint-of-care testingPOCTrapid testingrapid diagnostic testlateral flow assayfluorescence immunoassaybedside testingdiagnostic hardwaresynthetic biologybiocomputingmedical device manufacturerlab-on-a-chipbiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shenzhen Readline Biotechnology Co., Ltd. Comparables

Compare Shenzhen Readline Biotechnology Co., Ltd. with similar companies based on industry and business-model similarity.

Shenzhen Readline Biotechnology Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Lansion Biotechnology Co., Ltd.
89%
Chengdu VACURE Biotechnology Co., Ltd.
86%
Assure Tech Hangzhou Co Ltd
78%

Shenzhen Readline Biotechnology Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CFeb 21, 2025
Series B ExtensionApr 14, 2023
Series BDec 9, 2022
Series A ExtensionNov 22, 2021
Series ADec 4, 2020
Angel
Jun 5, 2019

Key People

Founding team and executive leadership

JUNMEI WANG

总经理&创始人CEO&Co-Founder

Founding Team

Shenzhen Readline Biotechnology Co., Ltd. Investors

Notable investors and investment history

Shenzhen Readline Biotechnology Co., Ltd. investors
InvestorRounds
Oriental Fortune CapitalSeries B Extension, Series A Extension, Series B, Series A
Synergetic Innovation Fund ManagementSeries B Extension
深圳市力合科创股份有限公司Series A
Shenzhen Leaguer Venture CapitalSeries A Extension
CoBuilder PartnersSeries A Extension
松禾资本 (Green Pine Capital Partners)Series B, Series C, Series A Extension
CoStone CapitalSeries C, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 15, 2026

    Grew 18% QoQ, from 40 to 47 employees.

  • Jan 21, 2026

    Monthly visitors grew 41% MoM.

Shenzhen Readline Biotechnology Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shenzhen Readline Biotechnology Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shenzhen Readline Biotechnology Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersShenzhen
Employee Range49
Year Founded2017
Last FundingFeb 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?